Industry Focus Transcripts

The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.

Join us for a look at the incredible growth of e-sports and the opportunity it presents to various industry stakeholders, including game publishers, content networks, and the players themselves.

There are a lot of good bankers, but these seven are certainly among the best.

Two years ago we tossed out a terrible ballpark on the revenue Apple Music might be able to bring in for the tech giant. Today we talk about that mistake and how to set yourself up to make better projections.

Everyone makes mistakes, but the important thing is to learn from them.

We said what? That's the theme for Industry Focus this week, and we continue our discussion of bad calls with the help of some of the biggest names in the sector.

We said what? Let’s face it: Sometimes our predictions miss the mark, and with Rite Aid and Opko Health, they missed the mark by a lot. Here’s what we said, why we said it, and what we learned from our mistakes.

Everyone makes mistakes, but not many of us air them publicly. That's the theme of this week's "Industry Focus," starting with our prediction in 2015 that concerns about Wells Fargo's cross-selling culture were much ado about nothing.

We run through recent wearables market data from Strategy Analytics, check in on the major players, and talk about the long-term outlook for Fitbit.

Next Monday’s solar eclipse will span across the U.S., and solar energy production will be surprisingly affected.

As company management faces off against an activist investor, shareholders will vote to determine if he should have a place on the board.

With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.

Business development companies are undergoing a sea change as the asset class becomes more institutionalized.

Investors are backing away from the Snapchat operator as more and more red flags appear.

Instead of investing in medical or recreational marijuana companies, it might make more sense to buy this back-door marijuana stock. Also, this could be the best precision medicine stock to buy, and it isn't even a drugmaker.

You might not be able to fire the coach or have a say in drafting new players, but there are ways to invest in professional sports.

Two Fools try to decode what's going on with Twitter's DAU/MAU numbers. Plus, they through the figures on another banner quarter for the world's largest company.

Before you follow an advisor's advice on these topics, make sure you know the whole story.

The cast takes a retail focus with updates that encompass e-commerce, apparel deals, department stores, and more.

A huge drop for a huge, steady producer followed some pretty alarming news in Pioneer’s quarterly report.